

Understanding the Effects of Chronological and Functional Age on Dosage Selection in Older Adults

Ginah Nightingale, PharmD, MBA, BCOP
Associate Director of Medical and Scientific Learning Excellence
Global Medical Affairs, AbbVie
October 16, 2023

Disclosure:

- I am an employee of AbbVie but the content that I will present today is based on my own thoughts and experiences in my professional capacity as a Board Certified Pharmacist and Professor.
- All viewpoints provided are my own personal opinions and are not intended to reflect those of my employer, AbbVie.
- I wanted to recognize the late, great geriatric oncologist, Dr. Arti Hurria, who inspired the content included in the presentation.

Objectives:

1. Compare and contrast chronological age and functional age
2. Identify physiologic changes and clinical pharmacology considerations for older adults when selecting treatments and dosing regimens
3. Describe how the geriatric assessment can be used to identify vulnerabilities when selecting treatment options for older adults with cancer


Worldwide Population is Aging

Figure 1: Proportion of population aged 60-plus in 2012 and 2050

The proportion of the world's older population will rise dramatically over the next decades.

- 0-9%
- 10-19%
- 20-24%
- 25-29%
- 30+%
- No data

≤ 20% age 65+




≥ 25% age 65+



Source: UNDESA Population Division, Population Ageing and Development 2012, Wall Chart, 2012

Note: The boundaries shown on this map do not imply official endorsement or acceptance by the United Nations

U.S. Cancer Prevalence by Age



The Aging Spectrum




Pediatrics

Unique Populations

- Age-related physiologic changes
- Vulnerability to toxicity
- Dependence in activities of daily living
- Concerns with long-term effects of therapy

Geriatrics

What's the Relationship Between Chronologic Age and Functional Age?



✓ Start here



Chronologic Age Versus Functional Age in Older Adults with Cancer




Chronologic age
= 80 years



Chronological age alone is often a poor indicator of the physiological and functional status of older adults; age alone should not be the main factor guiding treatment decisions in oncology.

Age-related Physiologic Changes Influence Clinical Pharmacology and Dosage Selection

Age-related Physiologic Changes (Pharmacokinetic Considerations)




Age-related Physiologic Changes (Pharmacodynamic Considerations)

Pharmacodynamics is defined as the correlation between drug concentration at the receptor and the resulting effect (influenced by variations in receptor number, receptor affinity, cellular response) and by changes in functional organ reserves.

Examples:

- Older adults have increased sensitivity to anthracycline-induced cardiovascular effects, increased risk of cardiomyopathy
- Older adults have reduced bone marrow reserve which increases the risk for chemotherapy-induced myelosuppression

Hallmarks of aging: Reduced physiologic reserve



Physiologic reserve = Fuel available

- May not be obvious at rest
- Becomes apparent with a stressor

There is little clinical trial evidence to guide treatment decisions for (many) older adults




Older adults are underrepresented on cancer clinical trials



Older adults on clinical trials are often not representative of patients seen in clinical practice





“ Will I tolerate and benefit from cancer therapy? ”

Factors Affecting Individualized Treatment Decisions


Characteristics of the tumor (e.g., tumor genetics, molecular findings)

Characteristics of the anti-cancer treatment regimen (e.g., safety profile)

Characteristics of the patient (e.g., physiologic reserve, comorbidities)

Integrating Geriatric Assessments into Oncology Practice

Intersection of Geriatrics and Oncology



A Tailored, Personalized Approach

Tailoring Cancer Treatment and Dosage Selection



80 years

No major comorbidity, exercises regularly, no geriatric syndromes, life expectancy ~ 13years*



80 years

Compensated comorbidity, independent with activities, 1 fall in the past 6 months, life expectancy ~ 8.5 years*



80 years

Moderate cognitive impairment, dependent with activities, 3 falls, life expectancy < 5 years*

A Tailored, Personalized Approach

Tailoring Cancer Treatment and Dosage Selection



80 years

FIT: Similar tolerance and benefit as middle-aged patient.



80 years

Vulnerable: Decreased treatment tolerance. Consider a modified therapy plan.



80 years


Frail: Not likely to tolerate anti-cancer therapy; Consider supportive care.

Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update



Recommendations

- The geriatric assessment (GA) should be used to identify vulnerabilities or impairments that are not routinely captured in oncology assessments for all patients over 65 years old with cancer
- A GA should include high priority aging related domains known to be associated with outcomes in older adults with cancer: physical and cognitive function, emotional health, comorbid conditions, polypharmacy, nutrition, and social support



In patients over 65 years receiving chemotherapy, geriatric assessment should be used to identify vulnerabilities that are not routinely captured in oncology assessments.


Polypharmacy: The Other Drug Problem?

Defined as the use of ≥ 5 medications or the use of high-risk drugs



Polypharmacy: The Other Drug Problem?

More than an 1/3 of older Americans use ≥ 5 prescription drugs



The Influence of Polypharmacy in Older Adults with Cancer

- ↑ Risk of adverse drug events
- ↑ Risk of cognitive impairment
- ↑ Risk of depression
- ↑ Risk of disability
- ↑ Risk of falls
- ↑ Risk of healthcare resource utilization
- ↑ Risk of post-operative complications
- ↑ Risk of caregiver burden
- ↑ Risk of mortality
- ↑ Risk of drug-drug interactions

In Summary:

- Unique challenges exist when considering cancer treatment (dosage selection) in older adults with cancer. Chronological age, alone, is insufficient to guide treatment decisions.
- Functional age, determined by a geriatric assessment, can be useful to tailor cancer treatment in older adults with cancer.
- Broadening cancer therapy trials to capture not only chronologic age but functional age would allow clinicians to better identify subsets of older adults who are most vulnerable to morbidity and mortality.

Understanding the Effects of Chronological and Functional Age on Dosage Selection in Older Adults

Ginah Nightingale, PharmD, MBA, BCOP
Associate Director of Medical and Scientific Learning Excellence
Global Medical Affairs, AbbVie
October 16, 2023